SFE Investment Counsel boosted its stake in shares of Zoetis Inc (NYSE:ZTS) by 13.1% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 11,112 shares of the company’s stock after purchasing an additional 1,290 shares during the quarter. SFE Investment Counsel’s holdings in Zoetis were worth $951,000 at the end of the most recent quarter.
Other institutional investors also recently made changes to their positions in the company. Lavaca Capital LLC acquired a new stake in shares of Zoetis in the fourth quarter valued at $32,000. Acima Private Wealth LLC bought a new position in Zoetis in the fourth quarter valued at about $34,000. Ledyard National Bank boosted its holdings in Zoetis by 393.3% in the fourth quarter. Ledyard National Bank now owns 587 shares of the company’s stock valued at $50,000 after acquiring an additional 468 shares during the last quarter. Essex Investment Management Co. LLC bought a new position in Zoetis in the fourth quarter valued at about $53,000. Finally, Truewealth LLC boosted its holdings in Zoetis by 65.5% in the fourth quarter. Truewealth LLC now owns 758 shares of the company’s stock valued at $65,000 after acquiring an additional 300 shares during the last quarter. 92.87% of the stock is owned by hedge funds and other institutional investors.
In other news, insider Heidi C. Chen sold 2,500 shares of Zoetis stock in a transaction dated Monday, December 3rd. The stock was sold at an average price of $93.51, for a total transaction of $233,775.00. Following the transaction, the insider now owns 17,662 shares in the company, valued at approximately $1,651,573.62. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Roxanne Lagano sold 2,000 shares of Zoetis stock in a transaction dated Monday, December 31st. The shares were sold at an average price of $85.30, for a total value of $170,600.00. The disclosure for this sale can be found here. Insiders have sold a total of 33,455 shares of company stock worth $2,958,663 in the last quarter. 0.35% of the stock is currently owned by company insiders.
ZTS traded down $0.28 during midday trading on Tuesday, reaching $95.09. 15,696 shares of the company were exchanged, compared to its average volume of 2,661,516. The company has a current ratio of 4.06, a quick ratio of 2.63 and a debt-to-equity ratio of 3.04. Zoetis Inc has a one year low of $77.00 and a one year high of $96.57. The stock has a market cap of $45.82 billion, a P/E ratio of 39.65, a price-to-earnings-growth ratio of 1.62 and a beta of 0.88.
Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 14th. The company reported $0.79 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.02. Zoetis had a return on equity of 75.51% and a net margin of 20.35%. The business had revenue of $1.56 billion for the quarter, compared to analysts’ expectations of $1.53 billion. During the same quarter in the previous year, the business posted $0.69 EPS. Zoetis’s revenue for the quarter was up 7.1% on a year-over-year basis. As a group, equities analysts forecast that Zoetis Inc will post 3.11 EPS for the current year.
Zoetis declared that its board has authorized a stock buyback plan on Wednesday, December 12th that allows the company to buyback $2.00 billion in outstanding shares. This buyback authorization allows the company to reacquire up to 4.7% of its stock through open market purchases. Stock buyback plans are often a sign that the company’s board of directors believes its stock is undervalued.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, June 3rd. Stockholders of record on Thursday, April 18th will be issued a dividend of $0.164 per share. This represents a $0.66 annualized dividend and a dividend yield of 0.69%. The ex-dividend date is Wednesday, April 17th. Zoetis’s dividend payout ratio (DPR) is presently 27.50%.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and markets veterinary vaccines and medicines in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Read More: Lock-Up Period Expiration
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.